AstraZeneca and Quell to Develop Cell Therapies in $2B Deal for Type 1 Diabetes and IBD

AstraZeneca has partnered with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder in a potential deal worth over $2 billion. The collaboration will involve the development of autologous multi-modular Treg cell therapies, which are designed to suppress an overactive immune response seen in organ transplantation, inflammatory and autoimmune disease. As..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 12.
  • textsms

AstraZeneca and Quell to Develop Cell Therapies for Type 1 Diabetes and IBD in $2B Deal

AstraZeneca has announced a partnership with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder. The collaboration involves the use of Quell's T-regulatory (Treg) cell engineering toolbox to develop autologous multi-modular Treg cell therapies, which will be manufactured through to the end of the first-in-human clinical study. AstraZeneca has initial..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms

AstraZeneca and Quell to Develop Cell Therapies in $2B Deal for Type 1 Diabetes and IBD

AstraZeneca has teamed up with Quell Therapeutics to develop therapies for Type 1 diabetes and inflammatory bowel disorder, potentially putting over $2 billion on the line. AstraZeneca provided $85 million to get started, while the rest of the opportunity comes in the form of development and commercialization milestones and potential royalties down the line. Quell will be responsible for develop..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms